For pharmaceutical manufacturers, understanding GTN requires visibility across an increasingly complex mix of commercial rebates, Medicaid, 340B, MFP, and other programs. When the data behind these programs lives in silos, it can be difficult to see where programs intersect and understand their collective impact on GTN.

Claims-level data provides a critical layer of visibility into this picture. When connected with pricing, contracts, rebates, government pricing, payments, and payer data, it can provide a more complete view of net price and GTN exposure across programs.

Join Model N + Truzo for a webinar exploring how manufacturers can move beyond program silos toward greater end-to-end GTN transparency. We’ll examine the growing role of claims-level data, what HRSA’s revised 340B Rebate Model Pilot signals for the industry, and how analytics and AI can turn greater visibility into actionable insights.

We’ll explore:

• How claims-level data can fill critical gaps in GTN visibility
• How connecting data across programs creates a more complete view of net price and GTN exposure
• What HRSA’s revised 340B Rebate Model Pilot signals about the growing importance of claims-level data
• How 340B claims data helps complete the broader GTN picture
• How analytics and AI can surface trends, anomalies, and potential revenue leakage
• How Model N + Truzo bring together claims, pricing, contracts, rebates, and payments to support greater end-to-end GTN transparency

Michael Grosberg

VP Product Management,

Model N

Meghal Patel

Chief Product Officer,

Truzo
Model N